Itopride hydrochloride efficacy in the management of delayed gastric emptying in type 1 diabetis mellitus patients in the presence of autonomic neuropathy

Abstract

Aim. Evaluation of the itopride (Ganaton?, Abbot) therapy efficacy in the management of gastrointestinal (GI) symptoms and gastric motor function (GMF) in type 1 diabetis mellitus (T1DM) patients (pts) in the presence of GMF dysfunction and other forms of diabetic autonomic neuropathy (DAN). Materials and Methods. The total of 34 patients with T1DM, GMF dysfunction and DAN were selected for randomized, prospective, open-label, comparative study. The duration of the study was 6 weeks. The study group (17 pts) received itopride 150 mg total daily. The control group (17 pts) did not receive any treatment for GMF. А questionnaire was used for the assessment of gastrointestinal (GI) symptoms. Gastric emptying velocity was evaluated with 13C-octanoate breath test. Results. As a result of itopride therapy there was a statistically significant decrease in the amount of time (T1/2) needed for the gastric emptying. The median amount of time decreased from 89.0 [82.3; 101.0] min to 53.0 [82.3; 101.0] min (p

A prospective multicentric postmarketing observational study to characterize the patient population with reduced gastrointestinal motility among indian diabetic patients receiving itopride: The progress study

“…Efficacy of itopride was the key reason for using the same which is well established by studies performed by Venkatesh and Kulkarni[11] and Budennaya et al . [7] These observations revalidate the efficacy of itopride as a prokinetic agent.…”

“…[3] Moreover, our study demonstrated a significant improvement in symptoms of reduced GI motility after 4 and 8 weeks of itopride treatment, reiterating the findings from earlier studies. [711]…”

“…[89] A double-blind randomized study reported acceleration of solid and liquid gastric emptying in itopride group compared to the placebo group in patients with diabetic gastroparesis. [10] Similarly, few other studies exhibited significant decrease in the time of gastric emptying[7] and postprandial glucose level after itopride therapy. [2] Moreover, in combination with pantoprazole, a significant improvement in the severity and frequency of all symptoms was reported in diabetic gastroparesis patients.…”

“…It not only stimulates the release of acetylcholine but also inhibits its degradation thereby promoting GI motility. Thus, itopride exhibits a dual effect on the motility of the GI tract and is not reported to cause extrapyramidal side effects,[789] possibly because of its high polarity which may largely prevent it from crossing the blood–brain barrier. [7]…”